© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 13, 990-1000,
July 3, 2002
© 2002 Oxford University Press
ARTICLE |
Gene Expression Profiles of BRCA1-Linked, BRCA2-Linked, and Sporadic Ovarian Cancers
Affiliations of authors: A. A. Jazaeri, C. Sotiriou, K. R. Brantley, E. T. Liu, Division of Clinical Sciences of the National Cancer Institute, Gaithersburg, MD; C. J. Yee, J. Boyd, Departments of Surgery and Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
Correspondence to: Edison T. Liu, M.D., Genome Institute of Singapore, Capricorn Bldg., 1 Science Park Rd., Science Park II, Singapore 117604 (e-mail: gisliue{at}nus.edu.sg).
Background: Germline mutations in BRCA1 and BRCA2 are responsible for 5%–10% of epithelial ovarian cancers, but the molecular pathways affected by these mutations are unknown. We used complementary DNA (cDNA) microarrays to compare gene expression patterns in ovarian cancers associated with BRCA1 or BRCA2 mutations with gene expression patterns in sporadic epithelial ovarian cancers and to identify patterns common to both hereditary and sporadic tumors. Methods: Tumor samples from 61 patients with pathologically confirmed epithelial ovarian adenocarcinoma with matched clinicopathologic features were studied, including 18 with BRCA1 founder mutations, 16 with BRCA2 founder mutations, and 27 without either founder mutation (termed sporadic cancers). The cDNA microarrays contained 7651 sequence-verified features. Gene expression data were analyzed with a modified two-sided F test, with P<.0001 considered statistically significant. The expression level of six genes was also studied with reverse transcription–polymerase chain reaction. Results: The greatest contrast in gene expression was observed between tumors with BRCA1 mutations and those with BRCA2 mutations; 110 genes showed statistically significantly different expression levels (P<.0001). This group of genes could segregate sporadic tumors into two subgroups, "BRCA1-like" and "BRCA2-like," suggesting that BRCA1-related and BRCA2-related pathways are also involved in sporadic ovarian cancers. Fifty-three genes were differentially expressed between tumors with BRCA1 mutations and sporadic tumors; six of the 53 mapped to Xp11.23 and were expressed at higher levels in tumors with BRCA1 mutations than in sporadic tumors. Compared with the immortalized ovarian surface epithelial cells used as reference, several interferon-inducible genes were overexpressed in the majority of tumors with a BRCA mutation and in sporadic tumors. Conclusions: Mutations in BRCA1 and BRCA2 may lead to carcinogenesis through distinct molecular pathways that also appear to be involved in sporadic cancers. Sporadic carcinogenic pathways may result from epigenetic aberrations of BRCA1 and BRCA2 or their downstream effectors.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. I. Weberpals, K. V. Clark-Knowles, and B. C. Vanderhyden Sporadic Epithelial Ovarian Cancer: Clinical Relevance of BRCA1 Inhibition in the DNA Damage and Repair Pathway J. Clin. Oncol., July 1, 2008; 26(19): 3259 - 3267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. N. Landen Jr, M. J. Birrer, and A. K. Sood Early Events in the Pathogenesis of Epithelial Ovarian Cancer J. Clin. Oncol., February 20, 2008; 26(6): 995 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Cannistra BRCA-1 in Sporadic Epithelial Ovarian Cancer: Lessons Learned from the Genetics of Hereditary Disease Clin. Cancer Res., December 15, 2007; 13(24): 7225 - 7227. [Full Text] [PDF]
|
|
|
|
|
|
H. K. Dressman, A. Berchuck, G. Chan, J. Zhai, A. Bild, R. Sayer, J. Cragun, J. Clarke, R. S. Whitaker, L. Li, et al. An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer J. Clin. Oncol., February 10, 2007; 25(5): 517 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. DelloRusso, P. L. Welcsh, W. Wang, R. L. Garcia, M.-C. King, and E. M. Swisher Functional Characterization of a Novel BRCA1-Null Ovarian Cancer Cell Line in Response to Ionizing Radiation Mol. Cancer Res., January 1, 2007; 5(1): 35 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Castellano, J. F. Reid, P. Alberti, M. L. Carcangiu, A. Tomassetti, and S. Canevari New Potential Ligand-Receptor Signaling Loops in Ovarian Cancer Identified in Multiple Gene Expression Studies Cancer Res., November 15, 2006; 66(22): 10709 - 10719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Chen, C. A. Arciero, C. Wang, D. Broccoli, and A. K. Godwin BRCC36 Is Essential for Ionizing Radiation-Induced BRCA1 Phosphorylation and Nuclear Foci Formation. Cancer Res., May 15, 2006; 66(10): 5039 - 5046. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Aggarwal, D. Li Guo, Y. Hoshida, S. Tsan Yuen, K.-M. Chu, S. So, A. Boussioutas, X. Chen, D. Bowtell, H. Aburatani, et al. Topological and Functional Discovery in a Gene Coexpression Meta-Network of Gastric Cancer Cancer Res., January 1, 2006; 66(1): 232 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Tilton, L. G. Gerwick, J. D. Hendricks, C. S. Rosato, G. Corley-Smith, S. A. Givan, G. S. Bailey, C. J. Bayne, and D. E. Williams Use of a Rainbow Trout Oligonucleotide Microarray to Determine Transcriptional Patterns in Aflatoxin B1-Induced Hepatocellular Carcinoma Compared to Adjacent Liver Toxicol. Sci., December 1, 2005; 88(2): 319 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Sowter and A. Ashworth BRCA1 and BRCA2 as ovarian cancer susceptibility genes Carcinogenesis, October 1, 2005; 26(10): 1651 - 1656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Jazaeri, C. S. Awtrey, G. V.R. Chandramouli, Y. E. Chuang, J. Khan, C. Sotiriou, O. Aprelikova, C. J. Yee, K. K. Zorn, M. J. Birrer, et al. Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers Clin. Cancer Res., September 1, 2005; 11(17): 6300 - 6310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Eckel, C. Gennings, T. M. Therneau, L. D. Burgoon, D. R. Boverhof, and T. R. Zacharewski Normalization of two-channel microarray experiments: a semiparametric approach Bioinformatics, April 1, 2005; 21(7): 1078 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Hartmann, K. H. Lu, G. P. Linette, W. A. Cliby, K. R. Kalli, D. Gershenson, R. C. Bast, J. Stec, N. Iartchouk, D. I. Smith, et al. Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy Clin. Cancer Res., March 15, 2005; 11(6): 2149 - 2155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hibbs, K. M. Skubitz, S. E. Pambuccian, R. C. Casey, K. M. Burleson, T. R. Oegema Jr, J. J. Thiele, S. M. Grindle, R. L. Bliss, and A. P.N. Skubitz Differential Gene Expression in Ovarian Carcinoma: Identification of Potential Biomarkers Am. J. Pathol., August 1, 2004; 165(2): 397 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Lee, A. K. Hsu, J. Sajdak, J. Qin, and P. Pavlidis Coexpression Analysis of Human Genes Across Many Microarray Data Sets Genome Res., June 1, 2004; 14(6): 1085 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. El-Tamer, D. Russo, A. Troxel, L. P. Bernardino, R. Mazziotta, A. Estabrook, B.-A. Ditkoff, F. Schnabel, and M. Mansukhani Survival and Recurrence After Breast Cancer in BRCA1/2 Mutation Carriers Ann. Surg. Oncol., February 1, 2004; 11(2): 157 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Bani, M. I. Nicoletti, N. W. Alkharouf, C. Ghilardi, D. Petersen, E. Erba, E. A. Sausville, E. T. Liu, and R. Giavazzi Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts Mol. Cancer Ther., February 1, 2004; 3(2): 111 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Lancaster, H. K. Dressman, R. S. Whitaker, L. Havrilesky, J. Gray, J. R. Marks, J. R. Nevins, and A. Berchuck Gene Expression Patterns That Characterize Advanced Stage Serous Ovarian Cancers Reproductive Sciences, January 1, 2004; 11(1): 51 - 59. [Abstract] [PDF]
|
|
|
|
|
|
K. K. Zorn, A. A. Jazaeri, C. S. Awtrey, G. J. Gardner, S. C. Mok, J. Boyd, and M. J. Birrer Choice of Normal Ovarian Control Influences Determination of Differentially Expressed Genes in Ovarian Cancer Expression Profiling Studies Clin. Cancer Res., October 15, 2003; 9(13): 4811 - 4818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Dobbin, J. H. Shih, and R. Simon Questions and Answers on Design of Dual-Label Microarrays for Identifying Differentially Expressed Genes J Natl Cancer Inst, September 17, 2003; 95(18): 1362 - 1369. [Full Text] [PDF]
|
|
|
|
|
|
D. H. Roukos, N. J. Agnanti, E. Paraskevaidis, and A. M. Kappas Approaching the Dilemma Between Prophylactic Bilateral Mastectomy or Oophorectomy for Breast and Ovarian Cancer Prevention in Carriers of BRCA1 or BRCA2 Mutations Ann. Surg. Oncol., December 1, 2002; 9(10): 941 - 943. [Full Text] [PDF]
|
|
|
|
|
|
F. Bertucci, F. Eisinger, R. Tagett, H. Sobol, and D. Birnbaum Re: Gene Expression Profiles of BRCA1-Linked, BRCA2-Linked, and Sporadic Ovarian Cancers J Natl Cancer Inst, October 2, 2002; 94(19): 1506 - 1507. [Full Text] [PDF]
|
|
|
|
|
|
I. A. Hedenfalk Gene Expression Profiling of Hereditary and Sporadic Ovarian Cancers Reveals Unique BRCA1 and BRCA2 Signatures J Natl Cancer Inst, July 3, 2002; 94(13): 960 - 961. [Full Text] [PDF]
|
|